Linvoseltamab and Alcohol/Food Interactions

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with linvoseltamab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of linvoseltamab treatment causes the transient release of cytokines that may suppress CYP450 isoenzymes; however, the potential for drug-drug interactions due to this effect has not been clinically evaluated. According to the manufacturer, increased exposure to CYP450 substrate(s) is more likely from the start of linvoseltamab therapy (including the initial step-up dosing schedule) through 14 days after the initial 200 mg dose, as well as during and following cytokine release syndrome. Increased exposure to the affected CYP450 substrate(s) may increase the risk of substrate-related adverse effects.

MANAGEMENT: Caution is advised when linvoseltamab is coadministered with drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic range, and where minimal changes to concentration may lead to significant adverse reactions (e.g. carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics). Clinical and/or laboratory monitoring are recommended, particularly at the initial phase of treatment with linvoseltamab as well as during and after cytokine release syndrome. Individual product labeling for the CYP450 substrate(s) should be consulted for specific dosage adjustment recommendations.